Gondola AMPS therapy stimulates specific points on your feet to reactivate the brain areas that control movement and balance. A mechanical stimulation, precise, non-invasive, which in just 2 minutes increases safety in walking and improve your life and the lives of your loved ones. Gondola AMPS represents a breakthrough in Parkinson's care because of its proven efficacy and innovative approach.
DISCOVER GONDOLA IN 1 MINUTE
Find the serenity, you get immediate benefits.
The Gondola AMPS therapy is designed for regular, ongoing use and is compatible with treatments already underway. It is a 2-minute Parkinson's treatment that applies precise pressures at two specific points on both feet.
This stimulation helps reactivate brain areas involved in gait and balance management. Our Parkinson's treatment is a scientifically validated method, tested on thousands of patients over more than 10 years.
There is a way to live with Parkinson's and lead a fulfilling life despite the disease: you can directly experience the Gondola device at one of our partner centers.

The advantages of Gondola
Gondola represents a major advance in innovative Parkinson's treatments, offering a rapid, noninvasive, and scientifically supported solution for the treatment of motor symptoms caused by Parkinson's disease.
Gondola changes your life!
You will immediately notice an improvement in walking, balance, and greater stability.
Those who use Gondola have no doubts
There is no better testimonial than those who benefit from Gondola and live a life freer from the restrictions of Parkinson's every day. Innovative Parkinson's therapies like this one help people regain independence and security.
PAOLO'S TESTIMONY




This is with an expert to verify eligibility for you or a family member

Gondola Medical Technologies Ltd.
Route de la Corniche 4 - 1066 Epalinges, Switzerland

Gondola Medical Technologies is a Swiss MedTech company that has developed Gondola AMPS, a therapy for treating gait and balance disorders caused by Parkinson's.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 836225 and No. 946638.
